

# Driving Innovation to End the HIV Epidemic

Since the height of the HIV/AIDS epidemic, Gilead has advanced groundbreaking innovations that have helped take HIV from a fatal and debilitating disease to a manageable chronic condition. During the last 30 years, our investment in scientific research has been a driving force in developing treatment and prevention regimens that have helped make it possible for people to live to their fullest potential – whether diagnosed with or at risk for HIV.

These efforts have brought us to a pivotal point: we are now working toward the ambitious goal of ending the HIV epidemic in our lifetime.

Since 2001, Gilead has launched 12 new medicines for the treatment and/or prevention of HIV.

## 25+ pills vs. 1 pill

Patients with HIV took more than 25 pills, three times a day in the mid-1990s compared to just **one pill, once a day** since 2006<sup>1</sup>

## 39 years vs. 73 years

The life expectancy of a 20-year-old diagnosed with HIV in 1996 versus 2010<sup>2</sup>

1981

First cases of AIDS reported in the U.S.<sup>3</sup>

1994

AIDS is the leading cause of death for Americans aged 25-44<sup>4</sup>

1996

Highly-active antiretroviral therapy (HAART) is introduced, combining multiple HIV therapies into a powerful “cocktail”<sup>5</sup>

1997

AIDS-related deaths in the U.S. decline by 47% compared with the previous year, due largely to the use of HAART<sup>4</sup>



2006

Gilead and BMS launch the first-ever complete HIV regimen combined into one pill taken once a day

2010

The Ryan White HIV/AIDS Program is created, establishing the largest federal program designed for people with HIV. Today, the program serves over half of all people diagnosed with HIV in the U.S.<sup>6</sup>

2015

Results from a major international clinical trial show that starting HIV treatment as soon as possible after diagnosis significantly improves health outcomes for people with HIV<sup>7</sup>

Advancements in HIV treatment over the past decade have resulted in new medicines that are highly effective and have better long-term safety and tolerability for patients<sup>8</sup>

2019

The White House launches *Ending the HIV Epidemic: A Plan for America*, a new federal initiative to reduce new HIV infections in the U.S. by 90% by 2030<sup>9</sup>

The National Institutes of Health (NIH) confirms that people with HIV who take treatment daily and maintain an undetectable viral load have effectively no risk of transmitting HIV<sup>10</sup>



More than 30 years of investment in research to discover and develop new medicines for HIV treatment and prevention



Ongoing research to find a cure for HIV and \$30 million in funding awarded to global research institutions to support HIV cure initiatives



Patient support programs that increase access to prescribed medicines through co-pay assistance and the provision of free medication to those who qualify



\$100 million commitment over 10 years to support organizations working to address the HIV/AIDS epidemic in the Southern U.S. as part of the COMPASS Initiative™



Ongoing investment in medical education programs for healthcare providers



More than \$537 million in HIV-related contributions to U.S. nonprofits in the last decade – Gilead has been named the top corporate philanthropic funder of HIV/AIDS programs worldwide by Funders Concerned About AIDS five years in a row<sup>11</sup>



Partnership with Emory University since 2010 on AIDSvu.org, an online platform that visualizes data and disseminates insights on the U.S. HIV epidemic



Support for more than 300 organizations since 2010 through the FOCUS Program to promote best practices in routine HIV screening and linkage to care in accordance with CDC and other governmental guidelines

## We've come a long way, but we're not done.

Our commitment to scientific research and innovation during the last three decades has helped make HIV treatment and prevention safer, simpler, and more effective.

To maximize these benefits and end the HIV epidemic, patients must be able to quickly and easily access the best possible treatment regimen for their individual needs – a decision that should be made by doctors together with their patients.

We also know that it takes more than medicine to improve people's health and quality of life. That's why Gilead is committed to partnering with governments, community organizations, researchers, healthcare providers, and advocates to break down barriers to HIV treatment, care, and prevention – efforts critical to ending the HIV epidemic.

As we look to the future, Gilead scientists are working hard to develop the next generation of HIV treatment and prevention therapies that may make it even easier for some patients to take their medications.

We also remain committed to investing in research for a cure so that we can someday truly eliminate this disease once and for all.

Together, we can end the HIV epidemic.



### SOURCES

1. Astuti N, Maggiolo F. Single-Tablet Regimens in HIV Therapy. *Infectious Diseases and Therapy*. 2014;3(1):1-17.
2. Marcus J, Chao C, et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. *Journal of Acquired Immune Deficiency Syndromes*. 2016;1:73(1):39-46.
3. Centers for Disease Control and Prevention. *Morbidity and Mortality Weekly Report*. 1981;30(21).
4. Department of Health & Human Services. HIV.gov. A Timeline of HIV and AIDS. Accessed from <https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline>.
5. Lange, Joep, et al. The Discovery and Development of Antiretroviral Agents. *Antiviral Therapy*. 2014;19(3):5-14.
6. Kaiser Family Foundation. The Ryan White HIV/AIDS Program: The Basics. Accessed from <https://www.kff.org/hiv/aids/fact-sheet/the-ryan-white-hiv-aids-program-the-basics/>.
7. National Institutes of Health. Starting antiretroviral treatment early improves outcomes for HIV-infected individuals. Accessed from <https://www.nih.gov/news-events/news-releases/starting-antiretroviral-treatment-early-improves-outcomes-hiv-infected-individuals>.
8. Gunthard H, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. *JAMA*. 2016;316(2):191-210.
9. Department of Health & Human Services. HIV.gov. What is 'Ending the HIV Epidemic: A Plan for America'? Accessed from <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.
10. Rodger A, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *The Lancet*. 2019;393(10189):2428-2438.
11. Brainard D. The Washington Post. More than medicine: Ending the HIV epidemic. Accessed from <https://www.washingtonpost.com/brand-studio/wp/2019/09/06/more-than-medicine-ending-the-hiv-epidemic/>.